SeRNI

SeRNI Pharmaceuticals is a Spanish biotechnology company dedicated to the development of first-in-class therapeutic solutions for cardiovascular and inflammatory diseases. Founded as a spin-off from the Research Institute of the Hospital de la Santa Creu i Sant Pau (IR Sant Pau) and the Spanish National Research Council (CSIC), the company focuses on modulating the LRP1 receptor pathway. Their lead candidate, SER-101, is a therapeutic peptide designed to reduce inflammation and limit tissue damage following myocardial infarction. By targeting novel mechanisms in vascular biology, SeRNI aims to improve outcomes for patients with acute coronary syndromes and chronic inflammatory conditions. The company leverages decades of scientific research to address significant unmet needs in the management of ischemic events. SeRNI is currently progressing its lead programs through the pre-clinical stage with the goal of entering human clinical trials.